A carregar...
A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors
Class 3 MEK1 mutations disrupt the negative regulatory helix region of MEK1 and drive constitutive activation of both pMEK and pERK that is independent of RAF and of MEK phosphorylation. Targeting MEK with trametinib resulted in mixed clinical responses in class 3 MEK1 mutated Langerhans cell histio...
Na minha lista:
| Publicado no: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6954994/ https://ncbi.nlm.nih.gov/pubmed/31949931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.08.02 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|